Stereochemistry | RACEMIC |
Molecular Formula | C26H28N4O2.C4H4O4 |
Molecular Weight | 544.5983 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CC4(CN1CCC(CC1)N2C(=O)NC3=CC=CC=C23)OCC5=C(C=CC=C5)N6C=CC=C46
InChI
InChIKey=NGODOSILXOFQPH-BTJKTKAUSA-N
InChI=1S/C26H28N4O2.C4H4O4/c1-26(24-11-6-14-29(24)22-9-4-2-7-19(22)17-32-26)18-28-15-12-20(13-16-28)30-23-10-5-3-8-21(23)27-25(30)31;5-3(6)1-2-4(7)8/h2-11,14,20H,12-13,15-18H2,1H3,(H,27,31);1-2H,(H,5,6)(H,7,8)/b;2-1-
Zaldaride is a calmodulin antagonist known to produce inhibition of calmodulin-dependent voltage-gated ion channels including those of Ca2+, Na+, and K+. Zaldaride was also observed to inhibit nicotinic acetylcholine receptor (nAChR) channel currents. Zaldaride has been studied in clinical trials as a potential treatment for travelers diarrhea.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Treatment of traveler's diarrhea: 20 mg zaldaride maleate four times per day
Route of Administration:
Oral